Evaluation of Barbaloin and Gallic acid against Ovarian & Breast Cancer Cell-In-Vitro and In-Vivo Studies
DOI:
https://doi.org/10.63682/jns.v14i32S.8255Keywords:
Barbaloin, Gallic acid, MCF-7, OAW42, apoptosis, cell cycle arrest, Ehrlich ascites carcinomaAbstract
Aim: Ancient Indian medicine has long employed the xerophytic plant Aloe vera (Family: Liliaceae) to treat several diseases and disorders, including diabetes and cancer, despite the limited scientific validation of these claims. This study aimed to identify and characterize secondary metabolites from the ethanol extract of A. vera leaves and assess their anti-cancer effects. In-vitro cytotoxicity was assessed against human OAW42 (ovarian) and MCF-7 (breast) cancer cell lines, while the in-vivo antitumor efficacy was evaluated using the Ehrlich ascites carcinoma (EAC) tumour model in Wistar rat model.
Background: Among two prepared fractions of Aloe vera extraction such as ethyl acetate soluble fraction (EAF) and the chloroform fraction (CF), EAF executed higher potency compared to others and was further utilized to isolate bioactive compounds, Barbaloin (1) and Gallic acid (2), which exhibited significant anti-cancer activity in both in-vitro and in-vivo assays. We further examined the antitumor activity of the ethyl acetate extract and the isolated compounds effectively modulated tumour-associated parameters and restored various hematological indices in EAC tumour-bearing rat.
Objectives: The basic objective of this research work is to describe the significant molecular mechanism of barbaloin and gallic acid against the cancer activity against MCF-7 and OAW42 cancer cell lines in-vitro and in a Wistar rat model in-vivo.
Methods: Barbaloin and gallic acid demonstrated dose-dependent growth inhibition along with the significant IC50 values for barbaloin and gallic acid against MCF-7 and OAW42 cell lines. Flow cytometry revealed that both compounds induced apoptosis and G2/M cell cycle arrest. Western blot analysis exhibited modulation of apoptosis and cell cycle regulatory proteins. In-vivo studies in Wistar rats with Ehrlich ascites carcinoma demonstrated that barbaloin and gallic acid treatment decreased the significant parameters of cancers compared to controls.
Results: Comparing with barbaloin and gallic acid with their individual effect to the combination of those, the combination of these compounds exhibits promising anti-cancer activities both in the study of in-vitro and in-vivo. Tumor volume is quantified based on the volume of ascitic fluid, the number of viable tumor cells present in that fluid which can be surgically removed from the animal body.
Conclusion
In conclusion, this study demonstrates that barbaloin and gallic acid individually possess significant anti-cancer activities individually and in combination against MCF-7 breast cancer and OAW42 ovarian cancer cell lines in-vitro and in a Wistar rat model of Ehrlich ascites carcinoma in-vivo. The combination of barbaloin and gallic acid significantly decrease the viable cell count and increase the non-viable cell count.
Downloads
Metrics
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., &Jemal, A. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians.2018; 68(6):394-424.
Newman, D. J., &Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products.2020; 83(3): 770-803.
Salehi, B., Albayrak, S., Antolak, H., Kręgiel, D., Pawlikowska, E., Sharifi-Rad, M., &Sharifi-Rad, J. Aloe genus plants: From farm to food applications and phytopharmacotherapy. International Journal of Molecular Sciences.2018; 19(9): 2843.
Hęś, M., Dziedzic, K., Górecka, D., Jędrusek-Golińska, A., &Gujska, E.Aloevera (L.) Webb: Natural sources of antioxidants–a review. Plant Foods for Human Nutrition. 2019; 74(3):255-265.
Nayeem, N., Asdaq, S. M. B., Salem, H., &AHEl-Alfqy, S. Gallic acid: a promising lead molecule for drug development. Journal of Applied Pharmacy. 2016; 8(2):1-4.
Kahkeshani, N., Farzaei, F., Fotouhi, M., Alavi, S. S., Bahramsoltani, R., Naseri, R., &Bishayee, A. Pharmacological effects of gallic acid in health and diseases: A mechanistic review. Iranian Journal of Basic Medical Sciences. 2019; 22(3): 225-237.
Nan Wang, GuoliGan, Jihao Yang, &Luyao Wang. Barbaloin Promotes Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells: Involvement of Wnt/β-catenin Signalling Pathway. Curr Med Chem. 2022;29(39):6100-6111.
ZangZang, Wei Rui, Zi-Chen Wang, Da-Xin Liu, & Lin Du. Anti-proliferation and anti-metastasis effect of barbaloin in non-small cell lung cancer via inactivating p38MAPK/Cdc25B/Hsp27 pathway. Oncol. Rep. 2017 Aug;38(2):1172-1180.
Ivy Ghosh, Sabyasachi Banerjee, Subhasish Dutta, Himangshu Sekhar Maji, &Arijit Mondal. Exploring the anti-diabetic potential of Aloe vera: isolation and characterization of bioactive compounds. Natural Product Research. Taylor & Francis. 2025: 1-7.
Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010 Aug; 16;6(16):1794-805.
Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O’reilly T, Wotherspoon G, Winter J.A rat model of bone cancer pain. Pain. 2002 Mar; 1;96 (1-2): 129-40.
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., &Sakuragi, N. Apoptosis and molecular targeting therapy in cancer. BioMed Research International. 2014; 150845.
Visconti, R., Della Monica, R., & Grieco, D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. Journal of Experimental & Clinical Cancer Research. 2016; 35(1): 153.
Gavet, O., & Pines, J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Developmental Cell. 2010; 18(4): 533-543.
Gilreath, J. A., Stenehjem, D. D., & Rodgers, G. M. Diagnosis and treatment of cancer-related anemia. American Journal of Hematology. 2014; 89(2): 203-212.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
